The dual endothelin-1/ angiotensin II receptor (Dear) binds endothelin-1 (ET-1) and angiotensin II (ANG II) with equal affinities in the Dahl S/JR HS rat strain. To elucidate its physiological significance within the context of multiple receptor isoforms and diverse ET-1 and ANG II functions spanning blood pressure regulation, tumor proliferation, and angiogenesis, we characterized mouse Dear and Dear-deficient mice. Unlike null mutant models of ET-1, ANG II, and all other ET-1 and ANG II receptors, Dear Ϫ/Ϫ deficiency results in impaired angiogenesis, dysregulated neuroepithelial development, and embryonic lethality by embryonic day 12.5. Interestingly, mouse Dear does not bind ANG II, similar to Dahl R/JR HS rat Dear, but binds ET-1 and vascular endothelial growth factor (VEGF) signal peptide (VEGFsp) with equal affinities, suggesting a putative novel multifunction for VEGFsp and a parsimonious mechanism for coordination of VEGF-induced and Dear-mediated pathways. Consistent with its developmental angiogenic role, Dear inhibition results in decreased tumor growth in B16-F10 melanoma cell-induced subcutaneous tumor in female Dear ϩ/Ϫ /C57BL6 BC10 mice, but not in males (age 3.5 mo), and in 127 Cs radiation-induced orthotopic mammary tumors in SpragueDawley female rats (age range 3-6.5 mo). Altogether, the data identify Dear as a new player in angiogenesis during development downstream to, and nonredundant with, VEGF-mediated pathways, as well as a putative modulator of tumor angiogenesis acting within a gender-specific paradigm.endothelin-1 receptor; VEGF signal peptide; vascular development; neuroepithelial development; cardiac development VASCULAR NETWORK DEVELOPMENT, or vascularization, is a complex process whose key component paradigms, vasculogenesis, angiogenesis, and vascular remodeling, comprise interacting pathways involving or modulating vascular endothelial growth factor (VEGF)-A and its isoforms VEGF 121 , VEGF 165 , and VEGF 189 ; angiopoietins 1 and 2 and their respective receptor tyrosine kinases; flk-1 or VEGFR2 receptor; and Tie2 or angiopoeitin receptor (40). As with other processes, normal vascular development pathways are recruited into pathological pathways, producing a spectrum of pathological angiogenesis as seen in solid tumors, arthritis, and diabetes. While VEGF is a key regulator of vascularization in health and disease (7), the complexity of vascularization is nevertheless evident, as other key modulators of angiogenesis, defined by embryonic lethal phenotypes associated with abnormal embryonic and/or extraembryonic vascularization phenotypes, exist. These modulators represent diverse functional groups, such as transcription factors like hypoxia-inducible transcription factor (45) and HAND1 (34), energy metabolism regulators like Foxo1 (19), ion pumps like Na/Ca exchanger (9), integrins like 8 (58) and ␣7/1 integrin (17) and regulators of integrins like focal adhesion kinase (49), growth factors like transforming growth factor (TGF)-1 (31), signal transduction kinases like p38␣ mi...